CAR-T细胞治疗自身免疫性疾病的研究述评
王雪懿, 李本尚

Review of CAR-T cell therapy for autoimmune diseases
WANG Xueyi, LI Benshang
表2 CAR-T细胞治疗AID的临床实验
Tab 2 Clinical trials of CAR-T cell treatment for AIDs
DiseaseTarget antigen

CAR-T cell

source

Sample size/nDisease statusEfficacyReference
SLECD19Autologous1RefractoryDrug-free remission in 44 d[17]
CD19Autologous5RefractoryDrug-free remission within 3 months[18]
CD19Allogeneic3RefractoryClinical remission in 12 months[45]
BCMA & CD19Autologous1RefractoryDrug-free remission in 23 months[19]
BCMA & CD19Autologous13

Relapsed/refractory: 2.

Refractory: 11

11 cases: drug-free remission in 12‒46 months[46]
ASSCD19Autologous1RefractoryDrug-free remission in 180 d[24]
CD19Autologous1RefractoryDrug-free remission in 150 d[25]
CD19Autologous1RefractoryClinical and serological remission in 240 d[26]
SScCD19Autologous1RefractoryClinical and serological remission in 6 months[47]
CD19Autologous3RefractoryDrug-free remission in 15 months[48]
CD19Autologous1RefractoryClinical and serological remission in 11 months[49]
CD19Allogeneic2RefractoryDrug-free remission in 6 months[50]
MSCD19Autologous2RefractoryClinical remission in 100 and 28 d[51]
NMOSDBCMAAutologous12Relapsed/refractory11 cases: Drug-free remission in 5.5 months[52]
MGBCMAAutologous14RefractoryClinical remission within 6‒12 months[53]
CD19Autologous2RefractoryClinical remission in 4 and 6 months[54]
MMNCD19Autologous1RefractoryClinical and serological remission in 6 months[55]